Life Science and Healthcare Oncology
Manchester has been at the forefront of cancer therapy and research for over a century with the Christie Hospital opening its doors in 1901. When it joined with The University of Manchester and Cancer Research UK in 2006 the organisation became Manchester Cancer Research Centre (MCRC) and now leads the way on a global stage with its MCRC Biobank, High Energy Proton Beam Therapy and ground-breaking trials for mobile cancer screening units and new drugs like Osimertinib.
Read our blog: 'Six Reasons Why Manchester is The Destination for Businesses Innovating for Improved Cancer Care.'
MIDAS work with Cancer Research UK (CRUK) which provides links with CRUK’s Drug Discovery Unit working with industry partners to help drive the translation of research breakthroughs in the lab into new treatments for patients as quickly and cost-effectively as possible. In partnership with University College London, Manchester hosts our Lung Cancer Centre of Excellence. By working together with internationally renowned scientists and clinicians, CRUK-MI have a real and exciting opportunity to make significant advances in the prevention, diagnosis, treatment, and care of lung cancer.
Manchester’s Experimental Cancer Medicines Centre is the strategic lead for the Precision Medicine working group which looks at ways of offering standardised molecular profiling and developing initiatives for access to clinical trials and targeted agents matched to genomic findings.
ECMC collaborates with other ECMCs in the North of England to increase opportunities for patients to participate in early phase clinical trials including trials with targeted therapies.
Genomics and Clinical Trials
Genomic medicine and diagnostics lead the way in the cancer treatment and MIDAS are proud of our links with the city’s Centre for Genomic Medicine. The Manchester Centre for Genomic Medicine has an active programme of research exploring ways to increase the ability to personalise diagnosis, to understand the effect of gene changes, to predict response to drugs and to offer patients new treatment opportunities.
As part of the Manchester Biomedical Research Centre they link academic scientists with genomic medicine services, state of the art clinical trials facilities and the latest genomic technologies. Consequently, Manchester’s genomic medicine infrastructure is directly allowing implementation, development, and delivery of precision medicine.
MIDAS maintains a close working relationship with the National Institute for Health Research (NIHR) who can gather information about patient populations and care pathways helping innovators to match suitable patients to relevant studies, making the trial process in Manchester quicker and more efficient.
Explore 'On Cancer'
Cancer is one of The University of Manchester’s five research beacons; examples of pioneering discoveries, interdisciplinary collaboration and cross-sector partnerships that are tackling some of the biggest questions facing the planet. Policy@Manchester is the University’s sector-leading policy engagement unit, and the articles in On Cancer provide evidence-led recommendations to policymakers on the prevention, detection, and treatment of cancer.
Get in Touch

Deborah Walker Head of Business Development - Life Science and Healthcare
-
6 minutes
UK Biobank to move to Manchester Science Park
UK Biobank, the world’s most significant source of data and biological samples for health researchers, has been successful in its £127.6m to the UK Research and Innovation (UKRI)…
-
4 minutes
Manchester Twins With Tokyo to Offer Joint Research Experience
The University’s Faculty of Science and Engineering and the Graduate School of Science, University of Tokyo, are pleased to announce the launch of a dual award PhD programme which complements…
-
6 minutes
Bruntwood SciTech Unveils Plans For £60m Highly Specialist Lab Space at Manchester Science Park
Bruntwood SciTech, the UK’s leading property developer dedicated to the growth of the science and technology sector, is set to invest a further £60m into Manchester Science Park (MSP) and…
Related Events
Microscience Microscopy Congress 2023 incorporating EMAG 2023
Make sure your 2023 diary includes mmc2023 which is returning to Manchester from 4-6 July. As…
Peptide Self-Assembly International Conference 2023
Peptide research and development is fast expanding. The field of biomimetic and de novo designed…
Key Sectors
Manchester's breadth and depth of expertise enables cross-industry opportunities for collaboration and a world-class offer for the international investor.
Advanced Manufacturing
Manchester is at the heart of the UK’s largest manufacturing and advanced engineering…
Creative And Media
Manchester is recognised as one of Europe’s largest creative, digital and technology…
Digital and Technology
As well as being home to a fast-growing £5 billion digital ecosystem, Manchester is…
Financial, Professional And Business Services
Manchester is home to the largest regional financial, professional and business…
Net zero
Manchester offers access to world-leading research facilities, state-of-the-art…
Life Science and Healthcare
Home to world-leading research and development assets as well as the largest clinical…